TSH Biopharm (8432) Monthly Revenue

Market: TPEx (OTC) · Industry: Biotech & Medical · 東生華

TSH Biopharm (8432) reported revenue of NT$168.9 million for Oct 2026, +19.3% year on year and -48.1% from the previous month. Revenue for Jan–Oct 2026 was NT$1.34 billion (+19.8% year on year).

Year-on-year revenue growth: 8 months in a row. →

In Oct 2026, it ranked No. 49 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$97.7 million24/10Nov 2024 NT$92 millionDec 2024 NT$101.4 millionJan 2025 NT$83.8 millionFeb 2025 NT$109.2 million25/02Mar 2025 NT$94.1 millionApr 2025 NT$85.1 millionMay 2025 NT$93.8 millionJun 2025 NT$90.5 million25/06Jul 2025 NT$84.5 millionAug 2025 NT$95.3 millionSep 2025 NT$242.7 millionOct 2025 NT$141.6 million25/10Nov 2025 NT$118 millionDec 2025 NT$105.7 millionJan 2026 NT$107 millionFeb 2026 NT$70 million26/02Mar 2026 NT$108.8 millionApr 2026 NT$108.4 millionMay 2026 NT$126.1 millionJun 2026 NT$96.3 million26/06Jul 2026 NT$107 millionAug 2026 NT$124.8 millionSep 2026 NT$325.4 millionOct 2026 NT$168.9 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$168.9 million+19.3%-48.1%
Sep 2026NT$325.4 million+34.1%+160.8%
Aug 2026NT$124.8 million+30.9%+16.7%
Jul 2026NT$107 million+26.6%+11.1%
Jun 2026NT$96.3 million+6.4%-23.6%
May 2026NT$126.1 million+34.5%+16.3%
Apr 2026NT$108.4 million+27.4%-0.4%
Mar 2026NT$108.8 million+15.6%+55.5%
Feb 2026NT$70 million-35.9%-34.6%
Jan 2026NT$107 million+27.7%+1.3%
Dec 2025NT$105.7 million+4.2%-10.4%
Nov 2025NT$118 million+28.3%-16.7%
Oct 2025NT$141.6 million+45.0%-41.6%
Sep 2025NT$242.7 million+9.0%+154.6%
Aug 2025NT$95.3 million+7.4%+12.8%
Jul 2025NT$84.5 million+9.7%-6.6%
Jun 2025NT$90.5 million+30.0%-3.5%
May 2025NT$93.8 million+3.3%+10.2%
Apr 2025NT$85.1 million+13.0%-9.6%
Mar 2025NT$94.1 million+81.0%-13.8%
Feb 2025NT$109.2 million+217.6%+30.2%
Jan 2025NT$83.8 million-26.6%-17.3%
Dec 2024NT$101.4 million+41.2%+10.2%
Nov 2024NT$92 million+44.4%-5.8%
Oct 2024NT$97.7 million+7.6%-56.1%

Jan–Oct 2026 cumulative: NT$1.34 billion (+19.8% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: TSH Biopharm vs PEC / TSH Biopharm vs Lotus Pharm / TSH Biopharm vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16